Official Title
CDK13 Related Disorder : Clinical Phenotype, Neuropsychological Profile, Brain MRI Characteristics and Epigenetic Signature.
Brief Title
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature.
Protocol ID
NCT04382573
Lead Sponsor
University Hospital, Montpellier
Brief Summary
CDK13 related disorder is mainly characterised by developmental delay (DD) and
intellectual disability (ID), ranging from mild to severe, and malformation syndrome.
The aims of this study are first to better delineate the clinical phenotype, as well as
the neuropsychological profile, and the brain MRI characteristics; and, second, to study
the epigenetic signatures in a cohort of individuals with CDK13 intragenic pathogenic
variants. This work will conduct to a MD thesis of a clinical resident geneticist in
France.
Physician that will participate will fill an Excel sheet regarding the clinical and
neuropsychological assessment.
The investigators will be also happy to have either CD-ROM or a link to have access to
the brain MRI data as well as a DNA sample with a minimum 0.5ug of peripheral blood
genomic DNA. The investigators will gather the DNA in Montpellier genetic lab (Dr Mouna
BARAT) and send the batch to the Dr Sadikovic' lab.
Between 2019 and 2020, The investigators have already recruited data from individuals
with CDK13 pathogenic variants from France and several European genetic centres.
Detailed Description
The investigators aim to better understand and delineate the genetic syndrome CDK13 This
genetic disorder was described in Sepember 2016 in Nature Genetics (PMID 27479907).
Since this first publication of 6 individuals carrying the pathogenic mutation CDK13, 37
other individuals carrying a pathogenic mutation of CDK13 have been reported in the
litterature The investigators are seeking to better define the phenotype of individuals
with pathogenic variants of CDK13, to better understand intellectual functioning as well
as the strengths and weaknesses of intellectual functioning by collecting standardized
neuropsychological assessments already performed such as WPPSI/WISC and WAIS. For this
purpose, The investigators will gather clinical and neuropsychological data already
carried out in the context of care.
The investigators also aim to gather the cerebral MRI scans already performed in order to
better delimit the cerebral anomalies observed in individuals and if the sequence is
adapted, The investigators will perform VBM studies.
Finally, The investigators will attempt to identify an epigenetic signature in this
genetic disease. To this end, The investigators will collect genomic DNA from peripheral
blood already collected for genetic analysis and send an anonymized batch of samples to
our collaborator, Dr. Bekim Sadicovik. Dr. Bekim Sadicovik and his team will compare the
epigenetic DNA methylation-type markers with the corresponding sex and age controls. If
specific probes are abnormally methylated in CDK13 individuals, this will determine a
disease-specific epigenetic signature. The investigators will then be able to propose an
epigenetic signature for individuals with uncharacterized CDK13 variations (class 3,
VUS). This method will make it possible to define whether the variation is responsible
for the disease or not without going through functional analysis steps that are difficult
to implement routinely.
The expected benefits are a better understanding of CDK13 disease, keys to
neuropsychological rehabilitation, a better understanding of human brain functions, the
possibility of proposing an epigenetic signature for people in whom it is not possible to
decide whether a variation in the CDK13 gene is pathological or not
Study Period
-
Enrollment Count
100 participants
Eligibility Criteria
Inclusion criteria:
- CDK13 intragenic pathogenic SNV (Single Nucleotide Variant)
Exclusion criteria:
- no pathogenic SNV in CDK13
- no consent for the study
Filters
Congenital Heart Defects
Dysmorphic Facial Features and Intellectual Developmental Disorder
UNKNOWN
CHILD
ADULT
OLDER_ADULT